More encouraging news from another of the world’s drug giants. AstraZeneca says its vaccine, developed with Oxford University, has shown to be up to 90 per cent effective following trials in the U-K and Brazil involving 23-thousand people. Late-stage trials are also underway in the U-S, Japan, Russia, South Africa, Kenya and Latin America. The drugmaker says it will seek an emergency use listing from the World Health Organization  to make it available as soon as possible.  Health Canada has already begun its evaluation of AstraZeneca’s vaccine candidate.